CORE
🇺🇦
make metadata, not war
Services
Research
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non-Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
Authors
Esra Akbay
Abigail Altabef
+15 more
Liang Chen
Zhao Chen
Katherine Cheng
Jeffrey A. Engelman
Pasi A. Janne
Andrew L. Kung
Oliver Mikse
Jacob B. Reibel
Geoffrey I. Shapiro
Norman E. Sharpless
Xiaohong Tan
Tanya Tupper
Yuchuan Wang
Kwok Kin Wong
Sue Ann Woo
Publication date
1 January 2014
Publisher
Doi
Cite
View
on
PubMed
Abstract
To extend the results of a phase III trial in non-small cell lung cancer patients with adenocarcinomas harboring EML4-ALK fusion
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Carolina Digital Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
cdr.lib.unc.edu:8c97kx836
Last time updated on 24/11/2020
